合并HBV非小细胞肺癌化疗同时使用抗病毒治疗的必要性  

The Importance of Combined HBV Approach to Chemotherapy for Non-small Cell Lung Cancer while Adoption of Antivirus Therapy

作　　者：段林灿[1] 李高峰[1] 张勇[1] 叶联华[1] 

机构地区：[1]昆明医学院第三附属医院(云南省肿瘤医院)胸外科,云南省肿瘤研究所肺癌研究中心,昆明650118

出　　处：《中国肺癌杂志》2009年第6期472-472,共1页Chinese Journal of Lung Cancer

摘　　要：背景与目的肺癌已经成为当今世界对人类健康与生命危害最大的恶性肿瘤，化疗延迟或中止是影响其预后的原因之一。本研究旨在探讨合并HBV非小细胞肺癌患者化疗同时使用抗病毒治疗的必要性。 方法选择合并HBV的Ⅲa非小细胞肺癌患者60例，分为实验组和对照组，实验组采用NP方案化疗的同时加拉米夫定，对照组只用NP方案化疗，比较实验组和对照组的肝功能损伤、免疫功能损伤和HBV再激活有无统计学差异。Background and objective Lung cancer has become the most serious malignant tumor that threat the human beings＂ health and life, and chemotherapy postponing or suspending contributes to one of the prognostic causes. This research explores the importance of combined HBV approach to chemotherapy for non-small cell lung cancer while adoption ofantivirus therapy. Methods Select 60 cases of patients suffering from combined HBV IIIa non-small cell lung cancer, who are divided into two groups, the experimental group and control group. For the experimental group, a NP-approach chemotherapy is adopted along with addition of Lamivudine, while for the control group, only NP-approach is applied, in order to compare whether there is any statistical difference between the two groups in terms of damage to the functions of liver and immune system as well as reactivation of HBV.

关 键 词：非小细胞肺癌 乙型肝炎 抗病毒 

分 类 号：R734.2[医药卫生—肿瘤] R563.1[医药卫生—临床医学]